★McKinsey to contribute $125 million to Purdue bankruptcy over opioid sales advice

The Big Market Report Take

McKinsey & Company is contributing $125 million to Purdue Pharma's bankruptcy estate, settling claims related to its consulting advice on opioid sales. This isn't a new legal battle, but rather a final payment stemming from McKinsey's role in advising Purdue on boosting OxyContin sales even as the opioid crisis deepened. For investors, this marks yet another significant financial hit for a major consulting firm tied to the opioid epidemic, highlighting the increasing scrutiny and liability for professional services firms whose advice is later deemed to have contributed to societal harm. The key thing to watch is whether this sets a precedent for further litigation against consulting firms, auditors, or lawyers for their indirect roles in corporate malfeasance, potentially expanding the scope of professional liability across the financial sector.